Abstract
Background:
In Canada, published outcome data for COVID-19 come largely from the first 2 waves of the pandemic. We examined changes in demographics and 30-day outcomes after SARS-CoV-2 infection during the first 3 pandemic waves in Alberta and Ontario; for wave 3, we compared outcomes between those infected with a variant of concern and those infected with the original “wild-type” SARS-CoV-2.
Methods:
We conducted a population-based retrospective cohort study using linked health care data sets in Alberta and Ontario. We identified all-cause hospitalizations or deaths within 30 days after a positive result on a reverse transcription polymerase chain reaction test for SARS-CoV-2 in individuals of any age between Mar. 1, 2020, and June 30, 2021, with genomic confirmation of variants of concern. We compared outcomes in wave 3 (February 2021 to June 2021) with outcomes in waves 1 and 2 combined (March 2020 to January 2021) after adjusting for age, sex and Charlson Comorbidity Index score. Using wave 3 data only, we compared outcomes by vaccination status and whether or not the individual was infected with a variant of concern.
Results:
Compared to those infected with SARS-CoV-2 during waves 1 and 2 (n = 372 070), we found a shift toward a younger and healthier demographic in those infected during wave 3 (n = 359 079). In wave 3, patients were more likely to be hospitalized (adjusted odds ratio [aOR] 1.57, 95% confidence interval [CI] 1.46–1.70) but had a shorter length of hospital stay (median 6 days v. 7 days, p < 0.001) and lower 30-day mortality (aOR 0.73, 95% CI 0.65–0.81). The 217 892 patients in wave 3 who were infected with a variant of concern (83.5% confirmed to have the Alpha variant, 1.7% confirmed to have the Delta variant) had a higher risk of death (Alpha: aOR 1.29, 95% CI 1.16–1.44; Delta: aOR 2.05, 95% CI 1.49–2.82) and hospitalization (Alpha: aOR 1.59, 95% CI 1.53–1.66; Delta: aOR 1.88, 95% CI 1.64–2.15) than those infected with wild-type SARS-CoV-2.
Interpretation:
We observed a shift among those infected with SARS-CoV-2 toward younger patients with fewer comorbidities, a shorter length of hospital stay and lower mortality risk as the pandemic evolved in Alberta and Ontario; however, infection with a variant of concern was associated with a substantially higher risk of hospitalization or death. As variants of concern emerge, ongoing monitoring of disease expression and outcomes among vaccinated and unvaccinated individuals is important to understand the phenotypes of COVID-19 and the anticipated burdens for the health care system.
Since December 2020, the World Health Organization has recognized SARS-CoV-2 variants of concern.1,2 Although reports from the United Kingdom, Europe and China have suggested that infections with variants of concern are more severe,3–12 until very recently there has been a paucity of evidence from North America.13,14
In Canada, wave 3 of the COVID-19 pandemic occurred between February and June 2021 (www.covid19tracker.ca) and was driven by variants of concern, particularly the Alpha (B.1.1.7) and Delta (B.1.617) variants; the Gamma (P1) and Beta (B.1.351) variants were seen largely in travellers returning from regions where these were more common. The Alpha variant has been associated with higher risks of mortality (approximately 64% in a UK case–control study and 59% in a UK cohort study)5,6 and hospitalization (52% in a UK cohort study6 and approximately 70% in European Surveillance System data).7 However, the UK studies5,6 relied solely on findings from community tests; they omitted up to 70% of COVID-19 deaths, which occurred in patients diagnosed after hospital admission. In the European study,7 less than 1% of specimens positive for SARS-CoV-2 were sequenced for variants. A Danish study also reported higher hospitalization rates with the Alpha variant, but this finding was based on only 128 hospitalizations (of 1235 in total), and the difference was detected only in adjusted analyses.8
Questions remain about disease severity and trajectories (i.e., the timing of hospitalizations or death) with variants of concern compared to the original “wild-type” SARS-CoV-2 clade in North America — crucial information for health system planners. In particular, given emerging evidence that the Delta and Omicron variants replicate more quickly, and that individuals infected with these strains have much higher viral loads, there is an urgent need to define the phenotypes of infection with variants of concern, because they rapidly become the most common circulating strain.
In this study, we examined changes in demographics and 30-day outcomes among people in Alberta and Ontario who were infected with SARS-CoV-2 over the first 15 months (3 waves) of the COVID-19 pandemic. To quantify the effect on outcomes of variants of concern, we compared event rates during wave 3 to those in waves 1 and 2, which were caused by wild-type SARS-CoV-2. Studies are ongoing to examine outcomes with newer variants of concern, such as Omicron.
Methods
Study design and setting
We conducted a retrospective cohort study in 2 of Canada’s most populous provinces — Alberta and Ontario; these provinces were the first to have linkable access to province-wide SARS-CoV-2 testing data, and they include over half of the Canadian population. Health care in Canada is government-funded, with free universal access to hospital, emergency department and physician services; each province is the legal custodian of health data for its citizens.
Participants
The study population included all people of any age (outpatients and inpatients) with a positive result from a SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) nasopharyngeal swab between Mar. 1, 2020, and June 30, 2021, and with genomic confirmation of all screen-positive tests for variants of concern after Feb. 7, 2021.
Data sources
We linked several province-wide administrative health data sets, deterministically using encrypted unique health identifier numbers to create our study’s analytical data set. Specifically, we linked RT-PCR testing data for SARS-CoV-2 from the Alberta and Ontario provincial laboratories with databases in each province that captured emergency department visits (National Ambulatory Care Reporting System), hospitalizations (Discharge Abstract Database) and COVID-19 vaccination status (see Appendix 1, available at www.cmajopen.ca/content/10/2/E400/suppl/DC1, for data sources and definitions. Vaccinations became available in both provinces in December 2020, initially for high-risk individuals only but with rapid expansion to the general adult population within 2 months as vaccine supply permitted. An individual was defined as fully vaccinated if at least 2 weeks had passed since their second dose of an approved COVID-19 vaccine; partially vaccinated if they had received at least 1 dose but did not yet meet the definition for fully vaccinated at the time of their positive SARS-CoV-2 RT-PCR test; unvaccinated).15
We extracted information on demographics, geographic locale and deaths from the health care insurance registry files of each province using the same deterministic linkage of unique health identifier numbers.
Definitions: cases, index dates and outcomes
For patients who were tested more than once during our study period, we examined only the data related to their first positive SARS-CoV-2 test. The index date was the date of their first positive RT-PCR test. Outcomes examined included emergency department visits, hospitalizations or deaths in the first 30 days after a positive result from an RT-PCR test.
Covariates
We identified comorbidities for each patient and generated their score on the Charlson Comorbidity Index16 using standardized case definitions from the International Classification of Diseases, 10th Revision, Canadian version (previously validated in Alberta and Ontario; Appendix 1).17 We based the identification of comorbidities on all hospitalizations in the 2 years up to and including the index date for each individual.
Statistical analysis
We have presented summary statistics, stratified according to the timing of the positive SARS-CoV-2 result (wave 1: Mar. 2020 to Oct. 2020; wave 2: Nov. 2020 to Jan. 2021; wave 3: Feb. 2021 to June 2021) and, for cases detected during wave 3, whether they were infected with a variant of concern or wild-type SARS-CoV-2. We compared outcome risks after adjusting for age, sex and Charlson Comorbidity Index score (which includes the most important of the QCovid18 risk score factors, such as diabetes, pulmonary disease, kidney disease, heart failure, neurologic disease and cancer). We conducted all analyses using SAS version 9.4 (SAS Institute) for each province separately. We then pooled the adjusted odds ratios (aORs) for each province using meta-analysis.
Although both Alberta and Ontario used a common protocol and common case definitions for comorbidities, several potential sources of heterogeneity remained between the provinces (e.g., differences in populations, drug formulary restrictions, data capture and SARS-CoV-2 testing priorities). Therefore, as per the convention of the Canadian Network for Observational Drug Effect Studies,19 we conducted a random effect meta-analysis using “metafor” in R package version 1.4–0 (http://CRAN.R-project.org/package=metafor). We used the restricted maximum likelihood estimator to estimate population heterogeneity because of its high efficiency compared to other estimators when the number of effect sizes is small.
Ethics approval
Ethical approval for this study was granted by the Health Research Ethics Board of the University of Alberta (Pro00101096). Signed informed consent from individual patients was waived for the Alberta data because we were analyzing de-identified health care administrative data. The use of Ontario data was authorized under section 45 of Ontario’s Personal Health Information Protection Act and did not require review by a research ethics board.
Results
Compared to the 372 070 cases of SARS-CoV-2 infection identified in waves 1 and 2 (March 2020 to January 2021), we observed a leftward shift in age distribution for the 359079 cases identified in wave 3 (February to June 2021; Table 1). We found a similar positivity rate across all 3 waves (5.2% of samples, overall).
Table 1:
Demographics and outcomes for those with SARS-CoV-2 infection in Alberta and Ontario — Mar. 1, 2020, to June 30, 2021
| Characteristic | Wave 1 (Mar. 2020 to Oct. 2020) | Wave 2 (Nov. 2020 to Jan. 2021) | Wave 3 (Feb. 2021 to June 2021) | Total | p value* |
|---|---|---|---|---|---|
| No. of people with a positive SARS-CoV-2 test | 100 478 | 271 592 | 359 079 | 731 149 | – |
| Age, yr, n (%) | |||||
| < 18 | 10 274 (10.2) | 36 367 (13.4) | 66 349 (18.5) | 112 990 (15.5) | < 0.0001 |
| 18–39 | 35 754 (35.6) | 96 585 (35.6) | 132 911 (37.0) | 265 250 (36.3) | < 0.0001 |
| 40–65 | 37 986 (37.8) | 103 488 (38.1) | 132 022 (36.8) | 273 496 (37.4) | < 0.0001 |
| > 65 | 16 464 (16.4) | 35 152 (12.9) | 27 797 (7.7) | 79 413 (10.9) | < 0.0001 |
| Age, yr, median (IQR) | |||||
| Alberta | 36 (23–51) | 36 (23–52) | 33 (19–47) | 35 (21–49) | < 0.0001 |
| Ontario | 43 (27–60) | 40 (25–57) | 36 (23–52) | 38 (24–55) | < 0.0001 |
| Male, n (%) | 48 523 (48.3) | 133 329 (49.1) | 182 622 (50.9) | 364 474 (49.8) | < 0.0001 |
| Rural resident, n (%) | 4968 (4.9) | 18 713 (6.9) | 24 116 (6.7) | 47 797 (6.5) | < 0.0001 |
| Deprivation Index, n (%) | |||||
| Missing | 2373 (2.4) | 7409 (2.7) | 8927 (2.5) | 18 709 (2.6) | < 0.0001 |
| Q1 (least deprived) | 16 782 (16.7) | 44 020 (16.2) | 62 711 (17.5) | 123 513 (16.9) | |
| Q2 | 16 809 (16.7) | 47 136 (17.4) | 65 702 (18.3) | 129 647 (17.7) | |
| Q3 | 18 004 (17.9) | 50 495 (18.6) | 66 885 (18.6) | 135 384 (18.5) | |
| Q4 | 18 909 (18.8) | 54 169 (19.9) | 69 639 (19.4) | 142 717 (19.5) | |
| Q5 (most deprived) | 27 601 (27.5) | 68 363 (25.2) | 85 215 (23.7) | 181 179 (24.8) | |
| In a long-term care facility, n (%) | 7832 (7.8) | 10 202 (3.8) | 826 (0.2) | 18 860 (2.6) | < 0.0001 |
| Charlson Comorbidity Index score, n (%) | |||||
| 0/missing | 90 174 (89.7) | 249 436 (91.8) | 334 113 (93) | 673 723 (92.1) | < 0.0001 |
| 1 | 2278 (2.3) | 4479 (1.6) | 3337 (0.9) | 10 094 (1.4) | |
| 2 | 1526 (1.5) | 2983 (1.1) | 2334 (0.6) | 6843 (0.9) | |
| 3+ | 6500 (6.5) | 14 694 (5.4) | 19 295 (5.4) | 40 489 (5.5) | |
| Specific comorbidities, n (%) | |||||
| COPD or asthma | 804 (0.8) | 1723 (0.6) | 1207 (0.3) | 3734 (0.5) | < 0.0001 |
| Other chronic lung disease (non-COPD/asthma) | 29 (0) | 65 (0) | 56 (0) | 150 (0) | 0.01 |
| Congestive heart failure | 1005 (1) | 1813 (0.7) | 1275 (0.4) | 4093 (0.6) | < 0.0001 |
| Hypertension | 3100 (3.1) | 5614 (2.1) | 4053 (1.1) | 12 767 (1.7) | < 0.0001 |
| Diabetes mellitus | 2655 (2.6) | 5280 (1.9) | 4231 (1.2) | 12 166 (1.7) | < 0.0001 |
| CAD (including previous MI, CABG or PCI/stent) | 898 (0.9) | 1996 (0.7) | 1901 (0.5) | 4795 (0.7) | < 0.0001 |
| Peripheral vascular disease | 218 (0.2) | 424 (0.2) | 335 (0.1) | 977 (0.1) | < 0.0001 |
| Cerebrovascular disease (previous stroke/TIA) | 678 (0.7) | 1110 (0.4) | 699 (0.2) | 2487 (0.3) | < 0.0001 |
| Atrial fibrillation/flutter | 1174 (1.2) | 1943 (0.7) | 1256 (0.3) | 4373 (0.6) | < 0.0001 |
| Ventricular arrhythmias | 67 (0.1) | 152 (0.1) | 130 (0) | 349 (0) | < 0.0001 |
| Renal disease | 489 (0.5) | 988 (0.4) | 725 (0.2) | 2202 (0.3) | < 0.0001 |
| Cancer | 706 (0.7) | 1654 (0.6) | 1752 (0.5) | 4112 (0.6) | < 0.0001 |
| Peptic ulcer disease | 178 (0.2) | 298 (0.1) | 282 (0.1) | 758 (0.1) | < 0.0001 |
| Liver disease | 191 (0.2) | 559 (0.2) | 544 (0.2) | 1294 (0.2) | < 0.0001 |
| Dementia | 1968 (2) | 2602 (1) | 621 (0.2) | 5191 (0.7) | < 0.0001 |
| Vaccination status, n (%) | |||||
| Fully vaccinated | 0 (0) | 8 (0) | 2500 (0.7) | 2508 (0.3) | < 0.0001 |
| Partially vaccinated | 0 (0) | 733 (0.3) | 22 378 (6.2) | 23 111 (3.2) | |
| Unvaccinated | 100 478 (100) | 270 851 (99.7) | 334 201 (93.1) | 705 530 (96.5) | |
| Death | |||||
| Death within 30 days, n (%) | 3423 (3.4) | 4800 (1.8) | 2639 (0.7) | 10 862 (1.5) | < 0.0001 |
| Age at death, yr, median (IQR) | |||||
| Alberta | 85 (77–91) | 85 (75–91) | 74 (63–85) | 84 (73–90) | < 0.0001 |
| Ontario | 86 (78–91) | 85 (76–91) | 76 (66–85) | 83 (73–90) | < 0.0001 |
| Male, n (%) | 1604 (46.9) | 2479 (51.6) | 1548 (58.7) | 5631 (51.8) | < 0.0001 |
| Days to death, median (IQR) | |||||
| Alberta | 7 (3–12) | 8 (4–13) | 9 (4–15) | 8 (4–13) | 0.009 |
| Ontario | 9 (5–14) | 11 (7–17) | 12 (6–19) | 11 (6–17) | < 0.0001 |
| All-cause hospitalization | |||||
| Hospital admission within 30 days | 7036 (7) | 13 025 (4.8) | 20 256 (5.6) | 40 317 (5.5) | < 0.0001 |
| Age at hospitalization, yr, median (IQR) | |||||
| Alberta | 63 (47–76) | 65 (48–80) | 54 (40–67) | 59 (44–74) | < 0.0001 |
| Ontario | 68 (54–81) | 70 (55–82) | 60 (46–73) | 64 (50–77) | < 0.0001 |
| Male, n (%) | 3737 (53.1) | 6977 (53.6) | 11 047 (54.5) | 21 761 (54) | 0.02 |
| Length of stay, d, median (IQR) | |||||
| Alberta | 6 (3–12) | 7 (3–13) | 5 (3–10) | 6 (3–11) | < 0.0001 |
| Ontario | 8 (3–20) | 7 (3–14) | 6 (3–12) | 7 (3–13) | < 0.0001 |
Note: CABG = coronary artery bypass graft, CAD = coronary artery disease, COPD = chronic obstructive pulmonary disease, IQR = interquartile range, MI = myocardial infarction, PCI = percutaneous coronary intervention, TIA = transient ischemic attack.
Waves 1 and 2 versus wave 3.
Hospitalizations within 30 days of a positive result were higher in wave 3 (5.6% v. 5.4%, p < 0.001), a difference that remained significant after adjusting for differences in demographics and comorbidity burdens (Alberta: aOR 1.51, 95% CI 1.44–1.58; Ontario: aOR 1.63, 95% CI 1.59–1.67; pooled: aOR 1.57, 95% CI 1.46–1.70 for wave 3 v. waves 1 and 2). However, hospital lengths of stay were shorter in wave 3 (Alberta: median 5 days v. 7 days; Ontario: median 6 days v. 7 days; both p < 0.001) than in waves 1 and 2. Patients with SARS-CoV-2 infection during wave 3 were also less likely to die within 30 days (0.9% v. 2.2%, p < 0.0001) than those in waves 1 and 2, even after adjusting for their younger age and lower comorbidity burdens (Alberta: aOR 0.68, 95% CI 0.61–0.76; Ontario: aOR 0.76, 95% CI 0.72–0.80; pooled: aOR 0.73, 95% CI 0.65–0.81).
Variants of concern versus wild-type strain in wave 3
Examining wave 3 data only, we found that 310 319 (86%) of the 359 079 patients with samples that were positive for SARS-CoV-2 between February and June 2021 were screened for variants of concern. Overall, 217 892 (70.2%) of those screened were confirmed positive for a variant: 182 020 (83.5%) for the Alpha variant and 3708 (1.7%) for the Delta variant (Table 2).
Table 2:
Demographics and outcomes for those with SARS-CoV-2 infection in Alberta and Ontario by variant — Feb. 1, 2021, to June 30, 2021 (wave 3)
| Characteristic | Wild-type | Alpha variant | Delta variant | Other variants | Not tested/ indeterminate | Total | p value |
|---|---|---|---|---|---|---|---|
| No. of people with a positive SARS-CoV-2 test | 92 427 | 182 020 | 3708 | 32 164 | 48 760 | 359 079 | – |
| Age, yr, n (%) | |||||||
| < 18 | 19 884 (21.5) | 31 875 (17.5) | 702 (18.9) | 5439 (16.9) | 8449 (17.3) | 66 349 (18.5) | < 0.0001 |
| 18–39 | 31 017 (33.6) | 69 101 (38.0) | 1409 (38.0) | 12 440 (38.7) | 18 944 (38.9) | 132 911 (37) | |
| 40–65 | 34 832 (37.7) | 67 697 (37.2) | 1290 (34.8) | 11 652 (36.2) | 16 551 (33.9) | 132 022 (36.8) | |
| > 65 | 6694 (7.2) | 13 347 (7.3) | 307 (8.3) | 2633 (8.2) | 4816 (9.9) | 27 797 (7.7) | |
| Age, yr, median (IQR) | |||||||
| Alberta | 32 (18–47) | 33 (20–47) | 32 (20–45) | 35 (22–48) | NA | 33 (19–47) | < 0.0001 |
| Ontario | 36 (23–54) | 36 (23–52) | 35 (22–52) | 36 (22–52) | 36 (22–53) | 36 (23–52) | < 0.0001 |
| Male, n (%) | 47 217 (51.1) | 92 315 (50.7) | 1898 (51.2) | 16 700 (51.9) | 24 492 (50.2) | 182 622 (50.9) | < 0.0001 |
| Rural resident, n (%) | 9317 (10.1) | 9856 (5.4) | 301 (8.1) | 1608 (5) | 3034 (6.2) | 24 116 (6.7) | < 0.0001 |
| Deprivation Index, n (%) | |||||||
| Missing | 3902 (4.2) | 3231 (1.8) | 69 (1.9) | 482 (1.5) | 1243 (2.5) | 8927 (2.5) | < 0.0001 |
| Q1 (least deprived) | 15 183 (16.4) | 32 650 (17.9) | 589 (15.9) | 5407 (16.8) | 8882 (18.2) | 62 711 (17.5) | |
| Q2 | 15 997 (17.3) | 34 327 (18.9) | 621 (16.7) | 5807 (18.1) | 8950 (18.4) | 65 702 (18.3) | |
| Q3 | 17 047 (18.4) | 34 328 (18.9) | 664 (17.9) | 6001 (18.7) | 8845 (18.1) | 66 885 (18.6) | |
| Q4 | 16 983 (18.4) | 36 044 (19.8) | 747 (20.1) | 6576 (20.4) | 9289 (19.1) | 69 639 (19.4) | |
| Q5 (most deprived) | 23 315 (25.2) | 41 440 (22.8) | 1018 (27.5) | 7891 (24.5) | 11 551 (23.7) | 85 215 (23.7) | |
| In a long-term care facility, n (%) | 326 (0.4) | 165 (0.1) | 32 (0.9) | 53 (0.2) | 250 (0.5) | 826 (0.2) | < 0.0001 |
| Charlson Comorbidity Index score, n (%) | |||||||
| 0/missing | 87 775 (95) | 169 547 (93.1) | 3368 (90.8) | 29 602 (92) | 43 821 (89.9) | 334 113 (93) | < 0.0001 |
| 1 | 943 (1) | 1475 (0.8) | 35 (0.9) | 263 (0.8) | 621 (1.3) | 3337 (0.9) | |
| 2 | 610 (0.7) | 1081 (0.6) | 29 (0.8) | 212 (0.7) | 402 (0.8) | 2334 (0.6) | |
| 3+ | 3099 (3.4) | 9917 (5.4) | 276 (7.4) | 2087 (6.5) | 3916 (8) | 19 295 (5.4) | |
| Specific comorbidities, n (%) | |||||||
| COPD or asthma | 360 (0.4) | 534 (0.3) | 7 (0.2) | 113 (0.4) | 193 (0.4) | 1207 (0.3) | < 0.0001 |
| Other chronic lung disease (non-COPD/asthma) | 16 (0) | 23 (0) | 1–5* | 1–5* | 10 (0) | 56 (0) | 0.02 |
| Congestive heart failure | 331 (0.4) | 577 (0.3) | 12 (0.3) | 113 (0.4) | 242 (0.5) | 1275 (0.4) | < 0.0001 |
| Hypertension | 1001 (1.1) | 1936 (1.1) | 46 (1.2) | 351 (1.1) | 719 (1.5) | 4053 (1.1) | < 0.0001 |
| Diabetes mellitus | 1124 (1.2) | 1935 (1.1) | 52 (1.4) | 366 (1.1) | 754 (1.5) | 4231 (1.2) | < 0.0001 |
| CAD (including previous MI, CABG or PCI/stent) | 443 (0.5) | 919 (0.5) | 22 (0.6) | 174 (0.5) | 343 (0.7) | 1901 (0.5) | < 0.0001 |
| Peripheral vascular disease | 83 (0.1) | 147 (0.1) | 3 (0.1) | 36 (0.1) | 66 (0.1) | 335 (0.1) | 0.008 |
| Cerebrovascular disease (previous stroke/TIA) | 185 (0.2) | 312 (0.2) | 8 (0.2) | 54 (0.2) | 140 (0.3) | 699 (0.2) | < 0.0001 |
| Atrial fibrillation/flutter | 330 (0.4) | 535 (0.3) | 18 (0.5) | 110 (0.3) | 263 (0.5) | 1256 (0.3) | < 0.0001 |
| Ventricular arrhythmias | 31 (0) | 63 (0) | 1–5* | 17 (0.1) | 17 (0) | 130 (0) | 0.5 |
| Renal disease | 181 (0.2) | 348 (0.2) | 1–5* | 53 (0.2) | 139 (0.3) | 725 (0.2) | 0.0002 |
| Cancer | 417 (0.5) | 831 (0.5) | 18 (0.5) | 169 (0.5) | 317 (0.7) | 1752 (0.5) | < 0.0001 |
| Peptic ulcer disease | 72 (0.1) | 124 (0.1) | 1–5* | 27 (0.1) | 55 (0.1) | 282 (0.1) | 0.04 |
| Liver disease | 173 (0.2) | 198 (0.1) | 8 (0.2) | 43 (0.1) | 122 (0.3) | 544 (0.2) | < 0.0001 |
| Dementia | 181 (0.2) | 212 (0.1) | 9 (0.2) | 51 (0.2) | 168 (0.3) | 621 (0.2) | < 0.0001 |
| Vaccination status, n (%) | |||||||
| Fully vaccinated | 334 (0.4) | 925 (0.5) | 111 (3) | 195 (0.6) | 935 (1.9) | 2500 (0.7) | < 0.0001 |
| Partially vaccinated | 3823 (4.1) | 11 722 (6.4) | 1010 (27.2) | 2100 (6.5) | 3723 (7.6) | 22 378 (6.2) | |
| Unvaccinated | 88 270 (95.5) | 169 373 (93.1) | 2587 (69.8) | 29 869 (92.9) | 44 102 (90.4) | 334 201 (93.1) | |
| Death | |||||||
| Death within 30 days, n (%) | 532 (0.6) | 1384 (0.8) | 52 (1.4) | 325 (1) | 346 (0.7) | 2639 (0.7) | < 0.0001 |
| Age at death, yr, median (IQR) | |||||||
| Alberta | 75 (63–86) | 74 (65–85) | 72 (69–80) | 66 (56–73) | NA | 74 (63–85) | 0.01 |
| Ontario | 79 (70–87) | 75 (65–84) | 73 (60–86) | 74 (65–84) | 78 (66–86) | 76 (66–85) | < 0.0001 |
| Male, n (%) | 302 (56.8) | 822 (59.4) | 30 (57.7) | 202 (62.2) | 192 (55.5) | 1548 (58.7) | < 0.0001 |
| Days to death, median (IQR) | |||||||
| Alberta | 8 (3–14) | 9 (4–17) | 12 (4–18) | 9 (3–14) | NA | 9 (4–15) | 0.4 |
| Ontario | 11 (6–17) | 12 (7–19) | 16 (11–21) | 13 (6–20) | 10 (4–16) | 12 (6–19) | < 0.0001 |
| All-cause hospitalization | |||||||
| Hospital admission within 30 days | 3470 (3.8) | 11 552 (6.3) | 295 (8) | 2321 (7.2) | 2618 (5.4) | 20 256 (5.6) | < 0.0001 |
| Age at hospitalization, yr, median (IQR) | |||||||
| Alberta | 55 (38– 69) | 54 (41–66) | 57 (39–69) | 53 (40–62) | NA | 54 (40–67) | 0.3 |
| Ontario | 63 (48–77) | 59 (46–71) | 57 (43–70) | 60 (48–72) | 61 (41–75) | 60 (46–73) | < 0.0001 |
| Male, n (%) | 1878 (54.1) | 6284 (54.4) | 169 (57.3) | 1335 (57.5) | 1381 (52.8) | 11 047 (54.5) | < 0.0001 |
| Length of stay, d, median (IQR) | |||||||
| Alberta | 5 (3–10) | 5 (3–10) | 6 (3–10) | 6 (3–10) | NA | 5 (3–10) | 0.8 |
| Ontario | 6 (3–11) | 6 (3–11) | 6 (3–11) | 7 (3–12) | 6 (2–11) | 6 (3–12) | < 0.0001 |
Note: CABG = coronary artery bypass graft, CAD = coronary artery disease, COPD = chronic obstructive pulmonary disease, IQR = interquartile range, MI = myocardial infarction, NA = not available, PCI = percutaneous coronary intervention, TIA = transient ischemic attack.
Cells with values of less than 5 have been suppressed for privacy reasons.
After adjusting for age, sex and comorbidities, infections with either the Alpha or Delta variant were associated with higher 30-day risks of death and hospitalization than wild-type infections during wave 3 (Table 3). However, the length of hospital stay and the time between a positive test result and death were similar among patients with variants of concern and wild-type infections in wave 3. Patients who were partially or fully vaccinated had a reduced risk of all-cause hospitalization or mortality in wave 3 in both Alberta and Ontario.
Table 3:
Outcome associations during wave 3, stratified by variant of concern and vaccination status*
| Variable | All-cause hospitalization, aOR (95% CI) | Death, aOR (95% CI) | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Alberta | Ontario | Pooled | Alberta | Ontario | Pooled | |
| Variant of concern | ||||||
|
| ||||||
| Wild-type | Reference | |||||
|
| ||||||
| Alpha variant | 1.86 (1.73–2.00) | 1.48 (1.41–1.56) | 1.59 (1.53–1.66) | 1.64 (1.32–2.04) | 1.19 (1.05–1.35) | 1.29 (1.16–1.44) |
|
| ||||||
| Delta variant | 2.7 (1.91–3.81) | 1.76 (1.52–2.04) | 1.88 (1.64–2.15) | 4.97 (2.37–10.43) | 1.67 (1.17–2.38) | 2.05 (1.49–2.82) |
|
| ||||||
| Vaccination status | ||||||
|
| ||||||
| Unvaccinated | Reference | |||||
|
| ||||||
| Partially vaccinated | 0.44 (0.38–0.51) | 0.42 (0.39–0.44) | 0.42 (0.40–0.45) | 0.61 (0.46–0.81) | 0.40 (0.35–0.46) | 0.43 (0.38–0.49) |
|
| ||||||
| Fully vaccinated | 0.55 (0.36–0.83) | 0.18 (0.15–0.22) | 0.22 (0.18–0.26) | 0.98 (0.55–1.77) | 0.33 (0.25–0.45) | 0.41 (0.32–0.53) |
Note: aOR = adjusted odds ratio, CI = confidence interval.
Adjusted for age, sex and Charlson Comorbidity Index score.
Interpretation
Our data describe disease severity phenotypes for SARS-CoV-2 variants of concern in Alberta and Ontario, information that is important for public health messaging and for health system planners. We found that the mortality risk was 29% higher with Alpha variant infections in Alberta and Ontario, consistent with effect estimates from the UK and Europe.4,5,7 However, given that wave 3 affected younger patients more than waves 1 and 2 (at least partially because of vaccination eligibility criteria), and given the increasing use of proven therapies such as corticosteroids over the course of the pandemic, we also found that the case fatality rate for those infected with SARS-CoV-2 was 27% lower in wave 3 than in the earlier waves, even though hospitalization risk increased by 57% in wave 3.
Our finding that people infected with a variant of concern were more likely to require hospitalization than those with wild-type SARS-CoV-2 was also consistent with reports from the UK and Europe (where over 80% of infections with variants of concern in wave 3 were the Alpha variant).6–8 Our finding of even higher event rates in those infected with the Delta variant also confirmed reports from China (hazard ratio [HR] 2.98, 95%CI 1.29–6.86 for deterioration to critical status with Delta-variant infections compared to wild-type infections),10 Scotland (85% higher risk of hospitalization with Delta-variant infections versus Alpha-variant infections)11 and England (adjusted HRs for hospitalization with the Delta variant versus the Alpha variant: 1.94 for vaccinated patients and 2.32 for unvaccinated patients).12 A recently published study from another group in Ontario also reported markedly higher risks of hospitalization and death in patients infected with the Delta variant (aORs of 2.08 and 2.32, respectively).13 In the United States, the risk of hospitalization with SARS-CoV-2 infection declined in the first 6 months of 2021, but it began increasing again after the Delta variant became the predominant strain in July and August 2021.14
These findings suggest that communities with ongoing high transmission rates of the Delta variant will experience major potential effects on health system capacity compared to previous waves of the pandemic. In particular, we note that the 8% hospitalization risk in those infected with the Delta variant during wave 3 in Alberta and Ontario was nearly double that seen with wild-type infections in earlier waves of the pandemic.
We found that vaccination against SARS-CoV-2 was associated with reduced chances of all-cause hospitalization or death in wave 3, even after adjusting for age, sex and comorbidity burden. To that end, it is worth noting that most hospitalizations in wave 3 occurred in unvaccinated or partially vaccinated individuals: for example, 91% of those hospitalized in Alberta during wave 3 were not fully vaccinated.20 As well, a recent US study found that vaccination was associated with a lower likelihood of hospitalization or death as a result of SARS-CoV-2 infection, and that vaccinated patients who were hospitalized had a substantially lower risk of progression to invasive mechanical ventilation.21 Preliminary data from England has demonstrated that the elevated HR for hospitalization among vaccinated individuals who were infected with the Delta variant was not significantly different than the HR for Delta-variant versus wild-type infections in those who were unvaccinated or partially vaccinated (p = 0.82).11,13,22 However, the absolute risks for hospitalization or poor outcomes were substantially lower in those who were vaccinated, even those infected with the Delta variant.
Our data on the effectiveness of vaccination in reducing hospitalizations and deaths as a result of SARS-CoV-2 variants of concern is consistent with other recent reports.21,23–26 Although ongoing genomic monitoring is crucial for detecting new variants of concern,27 we believe that it is just as important to ensure continued assessment of disease severity phenotypes in different jurisdictions, in vaccinated and unvaccinated individuals, and as variants of concerns evolve.
A major strength of our study was that most specimens that were positive for SARS-CoV-2 during wave 3 in Alberta and Ontario were screened for variants of concern, and samples that screened positive underwent subsequent genomic confirmation. In contrast, very low proportions were screened and had genomic confirmation in other studies describing disease severity in variants of concern (for example, only 0.7% in the recent report from the European Surveillance System).7
Limitations
A limitation of our analysis was that it was based largely on Alpha-variant infections, although we did have 30-day outcome data from over 3700 individuals infected with the Delta variant.3,6,7 As with other studies comparing variants of concern with wild-type infections, our sampling frame may have resulted in overestimates of absolute risks because minimally symptomatic or asymptomatic patients with infection were less likely to be tested (an example of collider bias).28 However, we examined all positive community cases, which was less biased than studying only hospitalized cases (which previous studies have done), and we found that sample positivity rates were similar in all 3 waves (approximately 5%).
To the extent that the Alpha or Delta variants may have been circulating in Alberta and Ontario before screening began for variants of concern, our results may have underestimated the impact of these variants on outcomes, because events in undiagnosed infections with variants of concern would have been classified as wild-type infections. It should be noted that the Public Health Agency of Canada update from Feb. 19, 2021,29 suggested that there were very few cases of variants of concern at the national level, even 10 days after widespread screening had started in Alberta and Ontario.
The duration of the presymptomatic stage (and the frequency of asymptomatic cases) with different SARS-CoV-2 strains has not yet been described and could not be assessed using our data set. As well, our use of the index hospitalization and any hospitalizations in the previous 2 years to define comorbidities and Charlson Comorbidity Index scores likely underestimated comorbidity burdens for community-dwelling individuals who had been relatively healthy. Moreover, because we did not have access to data on in-hospital treatments, we could not adjust for the impact of therapies that have proven beneficial in the treatment of COVID-19 (such as corticosteroids30) when we examined trends in mortality rates. We also could not account for potential differences in uptake of public health guidance (particularly with respect to social distancing and masking guidelines) between groups over the course of the pandemic.
Conclusion
The COVID-19 pandemic has evolved over time, with more infections in younger and healthier patients and more hospitalizations (but shorter lengths of stay and fewer deaths) in wave 3 than in earlier waves. However, high community transmission rates for variants of concern will lead to correspondingly high admission rates, adversely affecting health care capacity. These data indicate that the Alpha and Delta variants are associated with substantially higher risks of hospitalization or death than the wild-type strain in Alberta and Ontario. This finding is important for individual patient counselling to address vaccine hesitancy, and for public information campaigns that reinforce the need for continued risk-reduction measures such as social distancing and masking.
Supplementary Material
Acknowledgements
The Ontario portion of this study was supported by and conducted within ICES, which is funded by an annual grant from the Ontario Ministry of Health and the Ministry of Long-Term Care. Parts of this material are based on data and information provided by the Canadian Institute for Health Information and the Ministry of Health. Ontario Marginalization Index data are from the Ontario Community Health Profiles Partnership. These data were provided to ICES under section 45 of the Personal Health Information Act and may be used only for the “purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system.” The analyses, opinions, results, and conclusions expressed herein are solely those of the authors and do not necessarily reflect those of the funding or data sources; no endorsement is intended or should be inferred. The Alberta portion of this study was supported by and conducted within the Alberta Strategy for Patient Oriented Research Support Unit. This study is based in part on data provided by Alberta Health and Alberta Health Services. The interpretation and conclusions contained herein are those of the researchers and do not represent the views of the Government of Alberta or Alberta Health Services. Neither the Government of Alberta nor Alberta Health Services express any opinion in relation to this study.
Footnotes
Competing interests: None declared.
This article has been peer reviewed.
Contributors: Finlay McAlister, Majid Nabipoor, Douglas Lee, Lynora Saxinger and Jeffrey Bakal contributed to study concept and design; Majid Nabipoor, Anna Chu and Jeffrey Bakal acquired and analyzed the data; Finlay McAlister and Douglas Lee supervised the study and acquired funding; Finlay McAlister wrote the first draft; all authors revised drafts of the manuscript. All authors gave final approval of the version to be published and agreed to be accountable for all aspects of the work.
Members of the CORONA Collaboration: Husam Abdel-Qadir, Peter Austin, Kevin Bainey, Jeff Bakal, Charles de Mestral, Justin Ezekowitz, Shaun Goodman, Russ Greiner, Andrew Ha, Cynthia Jackevicius, Sunil Kalmady, Moira Kapral, Padma Kaul, Dennis Ko, Jeff Kwong, Douglas Lee, Peter Liu, Finlay McAlister, Paula Rochon, Idan Roifman, Heather Ross, Roopinder Sandhu, Michael Schull, Louise Sun, Jacob Udell, Sean van Diepen, Bo Wang, Robert Welsh, Cindy Westerhout, Harindra Wijeysundera, Amy Yu.
Funding: This work was supported by a COVID-19 Rapid Research Funding Opportunity grant (VR4 172736) from the Canadian Institutes of Health Research.
Data sharing: The data set from the present study is held securely in coded form on the Alberta Strategy for Patient Oriented Research Support Unit (AbSPORU) data platform (Alberta data) and at ICES (Ontario data). Legal data-sharing agreements between ICES, AbSPORU and the data providers (e.g., health care organizations and government) prohibit ICES or AbSPORU from making the data set publicly available; access may be granted to those who meet prespecified criteria for confidential access, available at https://www.ices.on.ca/DAS (email: das@ices.on.ca). The full data set creation plan and underlying analytic code are available from the authors upon request, on the understanding that the computer programs may rely on coding templates or macros that are specific to ICES, AbSPORU or both.
Editor’s note: An earlier version of this manuscript (with data only up to Mar. 31, 2021) appeared as a preprint on medRxiv at https://www.medrxiv.org/content/10.1101/2021.08.27.21261857v1.
Supplemental information: For reviewer comments and the original submission of this manuscript, please see www.cmajopen.ca/content/10/2/E400/suppl/DC1.
References
- 1.Fontanet A, Autran B, Lina B, et al. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet. 2021;397:952–4. doi: 10.1016/S0140-6736(21)00370-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Variants of the virus. Atlanta: Centers for Disease Control and Prevention; [accessed 2022 Feb. 28]. updated 2022 Feb. 25. Available: www.cdc.gov/coronavirus/2019-ncov/variants/about-variants.html. [Google Scholar]
- 3.Somerville M, Curran JA, Dol J, et al. Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review. BMJ Open. 2021;11:e055781. doi: 10.1136/bmjopen-2021-055781. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Davies NG, Jarvis CI, et al. CMMID COVID-19 Working Group. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;593:270–4. doi: 10.1038/s41586-021-03426-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Challen R, Brooks-Pollock E, Read JM, et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372:n579. doi: 10.1136/bmj.n579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Nyberg T, Twohig KA, Harris RJ, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ. 2021;373:n1412. doi: 10.1136/bmj.n1412. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Funk T, Pharris A, Spiteri G, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill. 2021;26:2100348. doi: 10.2807/1560-7917.ES.2021.26.16.2100348. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Bager P, Wohlfahrt J, Fonager J, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis. 2021;21:1507–17. doi: 10.1016/S1473-3099(21)00290-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 delta variant. Nat Commun. 2022;13:460. doi: 10.1038/s41467-022-28089-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Wang Y, Chen R, Hu F, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 delta VOC in Guangzhou, China. EClinicalMedicine. 2021;40:101129. doi: 10.1016/j.eclinm.2021.101129. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Sheikh A, McMenamin J, Taylor B, et al. SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397:2461–2. doi: 10.1016/S0140-6736(21)01358-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22:35–42. doi: 10.1016/S1473-3099(21)00475-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Fisman DN, Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. CMAJ. 2021;193:E1619–25. doi: 10.1503/cmaj.211248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Taylor CA, Patel K, Pham H, et al. Severity of disease among adults hospitalized with laboratory-confirmed COVID-19 before and during the period of SARS-CoV-2 B.1.617.2 (delta) predominance — COVID-NET, 14 states, January–August 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1513–9. doi: 10.15585/mmwr.mm7043e1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Summary of National Advisory Committee on Immunization statement of May 28, 2021. Ottawa: Government of Canada; 2021. [accessed 2022 Feb. 28]. Available: www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-updated-statement-may-28-2021.html. [Google Scholar]
- 16.Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676–82. doi: 10.1093/aje/kwq433. [DOI] [PubMed] [Google Scholar]
- 17.Tonelli M, Wiebe N, Fortin M, et al. Methods for identifying 30 chronic conditions: application to administrative data. BMC Med Inform Decis Mak. 2015;15:31. doi: 10.1186/s12911-015-0155-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.QCovid risk calculator. Oxford (UK): Oxford University; 2020. [accessed 2021 Nov. 30]. Available https://qcovid.org. [Google Scholar]
- 19.Canadian Network for Observational Drug Effect Studies. Montréal: CNODES; 2022. [accessed 2022 Feb. 28]. Available: www.cnodes.ca. [Google Scholar]
- 20.Total hospitalizations [table] Edmonton: Government of Alberta; 2022. [accessed 2022 Feb. 28]. Available: www.alberta.ca/stats/covid-19-alberta-statistics.htm#vaccine-outcomes. [Google Scholar]
- 21.Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326:2043–54. doi: 10.1001/jama.2021.19499. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Griffin JB, Haddix M, Danza P, et al. SARS-CoV-2 infections and hospitalizations among persons aged ≥ 16 years, by vaccination status — Los Angeles County, California, May 1–July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1170–6. doi: 10.15585/mmwr.mm7034e5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Sah P, Vilches TN, Moghadas SM, et al. Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants. EClinicalMedicine. 2021;35:100865. doi: 10.1016/j.eclinm.2021.100865. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Iorio A, Little J, Linkins L, et al. COVID-19 living evidence synthesis 6.30 — what is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? Hamilton (ON): McMaster Health Forum; 2022. Feb 25, [accessed 2022 Mar. 1]. Available: https://policycommons.net/artifacts/2263263/covid-19-living-evidence-synthesis-630/3022318/ [Google Scholar]
- 25.Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021;385:585–94. doi: 10.1056/NEJMoa2108891. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Nasreen S, Chung H, He S, et al. Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. medRxiv [preprint] 2021 Sep 30; doi: 10.1101/2021.06.28.21259420. [DOI] [PubMed] [Google Scholar]
- 27.Alam I, Radovanovic A, Incitti R, et al. CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants. Lancet Infect Dis. 2021;21:602. doi: 10.1016/S1473-3099(21)00078-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Griffith GJ, Morris TT, Tudball MJ, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020;11:5749. doi: 10.1038/s41467-020-19478-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Update on COVID-19 in Canada: epidemiology and modelling: February 19, 2021. Ottawa: Public Health Agency of Canada; 2021. [accessed 2022 Feb. 28]. Available: www.canada.ca/content/dam/phac-aspc/documents/services/diseases-maladies/coronavirus-disease-covid-19/epidemiological-economic-research-data/update-covid-19-canada-epidemiology-modelling-20210219-en.pdf. [Google Scholar]
- 30.RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. doi: 10.1056/NEJMoa2021436. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.